Search

file (10) (1)

OBI Information

News

HOMEWhat’s NewNews

2026.Apr.16

Media

OBI is featured in the Bioconjugate Insights on Bispecific and Dual-Payload ADC Design Strategies
Focusing on Approaches to Address Tumor Heterogeneity and Drug Resistance

2026.Apr.15

Corporate

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI® Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion™ ADC enabling technologies.

2026.Apr.09

Corporate

OBI Presents Obrion™ ADC Technologies at AntibodyChina 2026 in Shanghai
Highlighting Scalable Manufacturing and Bispecific Dual-Payload Design

2026.Apr.02

Corporate

OBI Participated in BIO-Europe Spring®, Advancing International Business Development
Engaged with Multiple Global Pharma Companies for Licensing Discussions

2026.Apr.01

Corporate

OBI Announces Final Arbitral Award in Contract Dispute with Biosion
Clinical Development and Global Strategy Continue as Planned with Related Programs Unaffected

2026.Mar.26

Corporate

OBI CEO Dr. Heidi Wang Invited to Speak at Biologics World Taiwan 2026 on Global Drug Regulatory Strategies

2026.Mar.12

Award & Certification​

OBI Is Awarded ABEA 2026 “Best ADC Developer in Taiwan”
CEO Heidi Wang Receives Women’s Leadership in ADC Development Award

2026.Mar.03

Corporate

OBI Receives Acceptance of Ten Abstracts at 2026 AACR
Advances Next-Generation ADC Development and Global Partnerships

2026.Feb.24

Corporate

OBI Presents Next-Generation Bispecific Dual-Payload ADC Development at World ADC London 2026

2025.Dec.19

Corporate

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

Announcements

Latest announcements

Events

Latest events